- Catalyst Pharmaceuticals reported its Q4 results highlighted by record revenues from its Firdapse drug, as the only FDA-approved treatment of LEMS disease.
- The company expects momentum to continue with the end of the pandemic allowing for new patients to be diagnosed and receive a prescription.
- Overall, solid fundamentals including recurring profitability, steady revenue profile, and new growth opportunities at an attractive valuation keep us bullish.
For further details see:
Catalyst Pharmaceuticals Inc.: Attractive Value Supported By New Growth Opportunities